Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis. [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating the efficacy and safety of subcutaneous tildrakizumab in adults with moderate to severe genital psoriasis; study is currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Genital Psoriasis
• Psoriasis

Drugs mentioned

• Ilumya (tildrakizumab)

Snippet

Sponsor: Sun Pharmaceutical Industries Limited | Conditions: Moderate to Severe Genital Psoriasis | Phase 3 | Status: ACTIVE_NOT_RECRUITING